title: Surveillance of transmitted drug-resistant HIV among young pregnant women in Ouagadougou, Burkina Faso.
abstract: Burkina Faso began rapid antiretroviral therapy (ART) scale-up in 2003 and by December 2009, 26,448 individuals were on treatment. With rapid scale-up of ART, some degree of human immunodeficiency virus transmitted drug resistance (TDR) is inevitable. Following World Health Organization methods, between June 2008 and July 2009, Burkina Faso assessed TDR in primigravid pregnant women aged <25 years attending antenatal care clinics in Ouagadougou, Burkina Faso. TDR was classified as moderate (5%-15%) for both nucleoside reverse-transcriptase inhibitors and nonnucleoside reverse-transcriptase inhibitors. The observed moderate TDR in Ouagadougou is a cause for concern and calls for closer monitoring of Burkina Faso's ART program.
authors.affiliation: Ministry of Health/BFA, HIV Surveillance, Ouagadougou, Burkina Faso. toniosomda@yahoo.fr
authors.forename: Antoine
authors.initials: A
authors.lastname: Somda
authors.forename: Lassana
authors.initials: L
authors.lastname: Sangare
authors.forename: Monique
authors.initials: M
authors.lastname: Soro
authors.forename: Saydou
authors.initials: S
authors.lastname: Yameogo
authors.forename: Babou
authors.initials: B
authors.lastname: Bazie
authors.forename: Françoise
authors.initials: F
authors.lastname: Bigirimana
authors.forename: Silvia
authors.initials: S
authors.lastname: Bertagnolio
authors.forename: Martine
authors.initials: M
authors.lastname: Peeters
authors.forename: Fatima
authors.initials: F
authors.lastname: Mouacha
authors.forename: Ana Maria
authors.initials: AM
authors.lastname: Rivera
authors.forename: Michael R
authors.initials: MR
authors.lastname: Jordan
authors.forename: Marie-Joseph
authors.initials: MJ
authors.lastname: Sanou
mesh_terms: D044966:Anti-Retroviral Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002050:Burkina Faso / Q000453:epidemiology; D024882:Drug Resistance, Viral; D005260:Female; D006678:HIV / Q000187:drug effects / Q000235:genetics*; D015658:HIV Infections / Q000453:epidemiology* / Q000635:transmission* / Q000821:virology; D006801:Humans; D011159:Population Surveillance; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000453:epidemiology* / Q000821:virology*; D055815:Young Adult
chemical_list: D044966:Anti-Retroviral Agents